NCT01595867View on ClinicalTrials.gov

Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And Placebo

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Narcotic AbuseOpioid-related DisordersAnalgesiaChronic Pain
Interventions
DRUG

Placebo

Lactose (100 mg) placebo tablets crushed; single dose

DRUG

EMBEDA - morphine sulfate/ naltrexone hydrochloride

EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose

DRUG

morphine sulfate CR crushed.

Morphine sulfate controlled release 30 mg tablet crushed

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY